Stay updated on Cabozantinib and Durvalumab Immuno-oncology Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    A new release version v3.5.2 was added and the previous v3.5.0 was removed.
    Difference
    0.1%
    Check dated 2026-04-18T12:56:51.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    Added a citation to iRECIST guidelines in the references and removed the corresponding erratum note.
    Difference
    0.1%
    Check dated 2026-04-04T05:08:02.000Z thumbnail image
  4. Check
    31 days ago
    Change Detected
    Summary
    Revision: v3.5.0 was added to the page. Revision: v3.4.3 was removed from the page.
    Difference
    0.1%
    Check dated 2026-03-20T19:51:12.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    Updated the iRECIST guideline reference to the Lancet Oncol 2017 guidelines (version 3.4.3), replacing the older 3.4.2 citation.
    Difference
    0.1%
    Check dated 2026-03-06T18:17:42.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    Minor version update from v3.4.1 to v3.4.2; study details and page layout remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-13T13:40:44.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    The page revision label changed from v3.4.0 to v3.4.1.
    Difference
    0.1%
    Check dated 2026-02-05T23:12:13.000Z thumbnail image

Stay in the know with updates to Cabozantinib and Durvalumab Immuno-oncology Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.